Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

EVIO Inc. Retires Convertible Debt

EVIO Inc.
Posted on: 25 Jun 18
EVIO Inc. Retires Convertible Debt

PR Newswire

BEND, Ore., June 25, 2018

Company continues to strengthen its balance sheet in conjunction with execution of North American expansion

BEND, Ore., June 25, 2018 /PRNewswire/ -- EVIO Inc. (OTCQB: EVIO) ("EVIO" or "the Company"), a leading provider of cannabis testing and scientific research for the regulated cannabis industry, announced today that floorless convertible notes issued pursuant to the company's 2017 debt offerings, which was raised to facilitate key acquisitions and expansion, have been fully retired and the Company has no further obligations under the notes of those offerings.  

"We're pleased to have these convertible debentures fully retired as we continue to strengthen EVIO's balance sheet and focus on improving shareholder value," said William Waldrop, CEO of EVIO. "As communicated with our shareholders last fall, the company is committed to using traditional types of financing to support our continued growth.  With California's additional mandated testing requirements coming into full force on July 1, and our continued expansion into growing marketplaces, we believe EVIO is well positioned to deliver growth in 2018 and beyond."

About EVIO Inc. (OTCQB: EVIO)
EVIO Inc. is a leading provider of cannabis testing and scientific research for the regulated cannabis industry. The Company's EVIO Labs division operates coast-to-coast providing state-mandated ancillary services to ensure the safety and quality of the nation's cannabis supply.  The Company's EVIO Biosciences Division is dedicated to the scientific, medical, and psychosocial exploration of clinical cannabis, cannabinoids, and the endocannabinoid system.
For more information, visit www.eviolabs.com.

Safe Harbor Statement
Any statements in this press release that are not statements of historical fact may be considered to be forward-looking statements. Statements may contain certain forward-looking statements pertaining to future anticipated or projected plans, performance and developments, as well as other statements relating to future operations and results. Words such as "may," "will," "expect," "believe," "anticipate," "estimate," "intends," "goal," "objective," "seek," "attempt," or variations of these or similar words, identify forward-looking statements. These forward-looking statements by their nature are estimates of future results only and involve substantial risks and uncertainties, including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, our ability to complete our product testing and launch our product commercially, the acceptance of our product in the marketplace, the uncertainty of the laws and regulations relating to cannabis, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed from time to time in our reports filed with the Securities and Exchange Commission, available at www.sec.gov or www.eviolabs.com

CONTACT INFORMATION
Company Contact:
Cheryl Kramp
Director of Marketing
EVIO Inc.
888.544.EVIO
info@EVIOLabs.com

 

View original content with multimedia:http://www.prnewswire.com/news-releases/evio-inc-retires-convertible-debt-300671155.html

SOURCE EVIO Inc.

PR Newswire
www.prnewswire.com

Last updated on: 25/06/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.